LINC00320: A Potential Drug Target for Neurodegenerative Diseases

Target Name: LINC00320

NCBI ID: G387486

Other Name(s): PRED14 | C21orf131 | NCRNA00320 | long intergenic non-protein coding RNA 320 | Long intergenic non-protein coding RNA 320, transcript variant 4

LINC00320: A Potential Drug Target for Neurodegenerative Diseases

LINC00320 (PRED14) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target for a variety of diseases.

The protein encoded by LINC00320 is composed of secondary structure of 21 kDa伪-helix and 21 kDa尾-helix. The 伪-helix of LINC00320 consists of 11 伪-helical units, of which 4 are at the N-terminus, 3 at the C-terminus, and 3 at the 尾-terminus. The 尾-helix consists of 6 尾-helix units, which are located inside the 伪-helix.

LINC00320's function in cells is being intensively studied. Research shows that LINC00320 plays a key role in neuronal differentiation and synapse formation. Loss of LINC00320 leads to neuronal apoptosis and may also play a role in tumorigenesis.

In addition, LINC00320 also plays an important role in cardiovascular diseases. Studies have shown that LINC00320 is associated with heart disease and diabetes, and may be involved in neurodegenerative diseases.

LINC00320 is also used as a target for therapeutic drugs. Currently, LINC00320 is used in combination with anti-neurodegenerative drugs, a type of drug that treats neurodegenerative diseases, to treat conditions such as Parkinson's disease and Alzheimer's disease.

In conclusion, LINC00320 is a promising drug target for the treatment of multiple neurodegenerative diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 320

More Common Targets